AstraZeneca

Open: 72.6 Close: 72.12 Change: -0.48

You don't have read the whole internet to decide whether to invest in AstraZeneca Company Inc. Use an AI.

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: China, AstraZeneca, …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

China accounted for 13% of Astrazenecas global sales last year. The company is Chinas biggest drugmaker.

Today's News

AstraZeneca considering spinning off its business in China and listing it in Hong Kong or Shanghai to shield it from geopolitical tensions. China made up 13% of AstraZecas global sales last year, bringing in revenues of nearly $6bn of a total $44bn. Astrazeneca may reportedly spin-off its Chinese business amid geopolitical tensions. Last year, the country accounted for 13% of AstraZenecas sales, and the company is Chinas biggest drugmaker. AstraZeneca is protecting itself from US-China tensions. The company would seek to be a patriotic company in China that loves the Communist Party, its China president said in May. China accounted for 13% of the companys sales last year. AstraZeneca could spin off its Chinese division and list it in Hong Kong to minimize China-related risks, the Financial Times reported on Monday. Cholesgen (Shanghai) has announced a three-year partnership with Astra. The EU is making a distinction between one brand of the AstraZeneca jab, named Vaxzevria, and its identical, but Indian-made version Covishield. The move could also exclude travelers from other countries that make local versions. AstraZeneca is the largest overseas pharmaceutical company in China by sales, generating $1.6 billion (€1.46 billion) in the country in the first quarter. The idea has been “on the table for a few years”, one adviser said.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: China, AstraZeneca, company, sale, year, tension, make, and the most common words in the summary are: astrazeneca, research, site, stock, news, china, business, . One of the sentences in the summary was: The company is Chinas biggest drugmaker.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #research #site #stock #news #china #business.